Patients during a mild to moderate acute attack of asthma (FEV1: 50 - 80% of predicted) were treated with Salmeterol MDI - 50mcg or Rotadisk - 50mcg or Salbutamol (MDI -200mcg). The children were followed by Spirometry, measuring FEV1 (basal) and after treatment: at 30 minutes, 60 minutes and thereafter every 60 minutes until 780 minutes, if the patients mantained the FEV1 above 80% of the predicted value and/or an increment of 20% in the VEF1 basal value. The Salmeterol group showed a significant bronchodilation at 60 minutes which was maintained in half of the patients up to 9 hours. This was not observed in the Salbutamol group: the peak bronchodilatation was observed at 30 minutes and the bronchodilation effect was observed in half of the patients up to 6 hours. There were no significant differences between both presentations of Salmeterol. This drug allowed a prolonged bronchodilator effect and is, according to the several consensus on management of asthma, an adequate option in the treatment of moderate to severe asthma.
O fator de impacto mede o número médio de citações recebidas em um ano por trabalhos publicados na revista durante os dois anos anteriores.
© Clarivate Analytics, Journal Citation Reports 2022
O CiteScore mede as citações médias recebidas por documento publicado. Mais informação
Ver maisSJR é uma métrica de prestígio baseada na idéia de que todas as citações não são iguais. SJR utiliza um algoritmo similar ao page rank do Google; é uma medida quantitativa e qualitativa ao impacto de uma publicação.
Ver maisSNIP permite comparar o impacto de revistas de diferentes campos temáticos, corrigindo as diferenças na probabilidade de ser citado que existe entre revistas de distintas matérias.
Ver mais